In our latest round-up, we look at the UK gift shop seeking registered trademark protection for "It's coming home", the new Cornish pasties authentication scheme, Kenya stepping up its anti-counterfeit efforts, and much more.
In our latest round-up, we look at Bayer deciding to retire the century-old Monsanto brand name, Kenzo prevailing in a trademark suit, Kenya Revenue authority destroying millions worth of fake alcohol, and much more.
The decision of the Court of Appeal of England and Wales in Holland and Barrett v General Nutrition provides valuable guidance for mark owners who license their main brand as well as a number of sub-brands. Read more
A new anti-sanction bill aimed at the prevention and suppression of unlawful and hostile foreign actions is now in force in Russia. Importantly, the bill generally does not concern the IP assets of foreign legal entities. Read more
The EU General Court has annulled a decision of the Board of Appeal of the EUIPO finding that there was a likelihood of confusion between Tillotts' XENASA mark and Ferring’s earlier PENTASA mark in Class 5. Read more
The EU General Court has annulled a decision of the Board of Appeal of the EUIPO, finding that there was a likelihood of confusion between the mark EMCURE in Classes 42 and 44 and the earlier mark EMCUR in Class 5.
Released today, Apple, Mars and Procter & Gamble head up the 2018 edition of the WTR 300: The World’s Leading Corporate Trademark Professionals. Now in its second edition, this community-led research project identifies the leading lights of the corporate trademark world. Read more
In the latest of our interview series with leading in-house counsel, The Chemours Company’s Deborah Hampton reflects on how paralegals are often underestimated and her approach to protecting the company’s global brand. Read more
In invalidity proceedings between Glaxo Group and Celon Pharma, the EU General Court has held that the Board of Appeal of the EUIPO did not have the competence to rule of its own motion on the earlier mark's genuine use.
A Lithuanian court has dismissed an action for the invalidation of the mark SATIMED for goods and services in Classes 3, 5 and 42, and the mark SATIVERA for goods in Class 3, based on the earlier marks SATIVEX. Read more
The EU General Court has considered whether the mark VSL#3 in Class 5 had become the common name in the trade for the products at issue, and whether the mark misled the public because of its use. Read more
In our latest industry data report, we explore the thriving and evolving healthcare industry. Our in-depth analysis reveals the trends driving this evolution, while also analysing key trademark filing statistics in this space. Read more
A deep dive into key data about the pharmaceuticals sector suggests that over-regulation and availability of skills and technology remain key challenges; while the leading brands continue to rise in value, most are still filing in single classes only Read more
In this week’s data report, we turn the spotlight on the sprawling pharmaceutical sector. We look at how the sector is being affected by political pressures, and identify the developments that are driving change. Read more
Two frameworks are applicable to pharmaceutical marks in Chile. The Industrial Property Law and its regulation set out the rules for the registration and use of trademarks; the Sanitary Code and Decree 3/2010 regulate the pharmaceutical product marketing authorisation procedure.
Sweeping amendments to the Trademarks Act are expected to be implemented in 2019. The amendments will fundamentally affect the way in which all trademark owners will need to approach their selection, clearance and registration strategies, and the pharmaceutical industry is no exception.
Brazil is a first-to-file jurisdiction, and therefore IP rights are acquired only when an application is filed and registered with the Brazilian Patent and Trademark Office. However, pharmaceutical trademarks fall under two separate and independent statutory regimes.
In order for a pharmaceutical trademark to be registered, no prior authorisation is needed per se. Unlike in other countries, in France the trademark owner is independent from the party exploiting the trademark and need not possess a particular quality.